Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The BCR/ABL hybrid gene.

J Groffen, N Heisterkamp

    Bailliere'S Clinical Haematology
    |December 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    The Philadelphia (Ph) translocation in chronic myeloid leukemia (CML) creates a BCR/ABL fusion gene. This fusion produces a novel protein that may drive CML development.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Parasite Infections Influence Immunological Responses But Not Reproductive Success of Male Hellbender Salamanders (<i>Cryptobranchus alleganiensis</i>).

    Integrative organismal biology (Oxford, England)·2025
    Same author

    Modulation of Paternal Care Behaviors in Response to Stream Conditions by Eastern Hellbenders (<i>Cryptobranchus alleganiensis alleganiensis</i>).

    Integrative organismal biology (Oxford, England)·2025
    Same author

    Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells.

    Leukemia·2014
    Same author

    Galectin-3 in pre-B acute lymphoblastic leukemia.

    Leukemia·2013
    Same author

    AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo.

    Blood cancer journal·2012
    Same author

    Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.

    Leukemia·2012
    Same journal

    Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

    Bailliere's clinical haematology·2000
    Same journal

    Pharmacological therapy.

    Bailliere's clinical haematology·2000
    Same journal

    Prenatal diagnosis and screening of the haemoglobinopathies.

    Bailliere's clinical haematology·2000
    Same journal

    Sickle cell disease: clinical management.

    Bailliere's clinical haematology·2000
    Same journal

    Pathophysiology of sickle cell disease.

    Bailliere's clinical haematology·2000
    Same journal

    Thalassaemia: clinical management.

    Bailliere's clinical haematology·2000
    See all related articles

    Area of Science:

    • Molecular Biology
    • Genetics
    • Oncology

    Background:

    • The Philadelphia (Ph) translocation is a hallmark of chronic myeloid leukemia (CML).
    • This translocation involves breakpoints on chromosomes 9 and 22, specifically within the BCR gene on chromosome 22.

    Purpose of the Study:

    • To investigate the molecular consequences of the Ph translocation in CML.
    • To identify the genetic and protein products resulting from the BCR/ABL fusion.

    Main Methods:

    • Analysis of DNA from CML patients and cell lines.
    • Detection and characterization of chimeric BCR/ABL transcripts.
    • Identification of abnormal ABL protein products.

    Main Results:

    • A specific DNA region, M-BCR, on chromosome 22 is consistently involved in the Ph translocation breakpoint.

    Related Experiment Videos

  • The Ph translocation fuses the 5' portion of the BCR gene with the 3' portion of the ABL oncogene.
  • Chimeric BCR/ABL mRNA transcripts and abnormally sized BCR/ABL proteins were detected in CML samples.
  • Conclusions:

    • The BCR/ABL fusion protein is the likely product of the chimeric mRNA in CML.
    • The BCR moiety may alter ABL protein activity, potentially conferring transforming capabilities.
    • The BCR/ABL protein is strongly implicated in the pathogenesis of CML.